Medicus Pharma Regains Compliance with Nasdaq Minimum Equity Requirement for Continued Listing
Key Highlights
- ➤Medicus Pharma (MDCX) regained Nasdaq equity compliance after $4.25 million equity financings.
- ➤Streeterville Capital exchanged $10.5 million debt for non-convertible preferred shares.
- ➤Compliance depends on evidencing minimum equity in the December 31, 2026 periodic report.
- ➤Failure to reestablish compliance could subject Medicus to Nasdaq delisting.
- ➤Medicus is advancing CD228V as the lead precision oncology program.
Expert Statements
Raza Bokhari, Executive Chairman and CEO of Medicus Pharma
“Nasdaq’s confirmation recognizes the progress we have made in strengthening Medicus’ balance sheet.”
Raza Bokhari, Executive Chairman and CEO of Medicus Pharma
“My most recent investment alongside other directors and officers reflects our commitment to the Company.”
Raza Bokhari, Executive Chairman and CEO of Medicus Pharma
“We remain focused on disciplined capital allocation and advancing CD228V as the lead program in our precision oncology portfolio.”
PHILADELPHIA, Nov. 19, 2026 (GLOBE NEWSWIRE) -- Medicus Pharma Ltd. (NASDAQ: MDCX) (“Medicus” or the “Company”), a precision-guided, biotech/life sciences company focused on advancing the clinical development programs of novel and potentially disruptive therapeutic assets, today announced that it has received written notification on November 18, 2026 (the “Conditional Compliance Notice”) from the Listing Qualifications Department of The Nasdaq Stock Market LLC ("Nasdaq") confirming that the Company has regained compliance with Nasdaq Listing Rule 5550(b)(1), which requires at least $2.5 million in shareholders’ equity for continued listing on The Nasdaq Capital Market.
Nasdaq based its determination on the transactions described in the Company’s Current Report on Form 8-K filed with the Securities and Exchange Commission (the “SEC”) on November 16, 2026. Additional details may be found in the Company’s Current Report on Form 8-K filed with the SEC today.
Get started
Create a free account to read the full story.
